Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413191 | 1.00 | S1PR2 (0.38) | S1PR2S1PR4S1PR3PGK1PGK2 | |
| SCHEMBL18415006 | 0.82 | IRAK4 (0.38) | S1PR2S1PR4S1PR3PGK1PGK2 | |
| SCHEMBL31691990 | 0.82 | IRAK4 (0.38) | S1PR2S1PR4S1PR3PGK1PGK2 | |
| SCHEMBL3298262 | 0.82 | PGK1 (0.50) | PGK1PGK2IDH1IRAK4ALDH1A1 | |
| SCHEMBL29651896 | 0.79 | S1PR2 (0.35) | S1PR2S1PR4S1PR3PGK1PGK2 | |
| SCHEMBL3510748 | 0.79 | S1PR2 (0.35) | S1PR2S1PR4S1PR3PGK1PGK2 | |
| SCHEMBL21264174 | 0.79 | IRAK4 (0.37) | S1PR2S1PR4S1PR3PGK1PGK2 | |
| SCHEMBL22834772 | 0.79 | S1PR2 (0.35) | S1PR2S1PR4S1PR3PGK1PGK2 | |
| SCHEMBL906775 | 0.78 | IRAK4 (0.41) | S1PR2S1PR4S1PR3PGK1PGK2 | |
| SCHEMBL30577788 | 0.78 | IRAK4 (0.41) | S1PR2S1PR4S1PR3PGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735430-A1 | MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4635944-A1 | 2-AZABICYCLO[3.1.1]HEPTANE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-10-22 | — | — | EP | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | DRAIG THERAPEUTICS LTD. (GB) | 2025-06-19 | — | — | US | disclosed |
| EP-2276759-B1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | LILLY CO ELI (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7932274-B2 | 3-indazolyl-4-pyridylisothiazoles | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| CN-101959883-A | 3-indazolyl-4-pyridylisothiazoles | LILLY CO ELI | 2011-01-26 | — | — | CN | disclosed |
| EP-2276759-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | Eli Lilly & Company (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009123855-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| CN-101001846-A | Novel alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2007-07-18 | — | — | CN | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | S1PR2 3022/4885S1PR4 3634/4885S1PR3 2819/4885 |
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | S1PR2 1455/4885S1PR4 1253/4885S1PR3 1375/4885 |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | S1PR2 458/4885S1PR4 612/4885S1PR3 460/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | S1PR2 958/4885S1PR4 697/4885S1PR3 881/4885 |
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | CYP3A4, IPO4, JAK3 | S1PR2 2390/4885S1PR4 1023/4885S1PR3 836/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | S1PR2 3132/4885S1PR4 3395/4885S1PR3 3336/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | S1PR2 1388/4885S1PR4 2195/4885S1PR3 1417/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | S1PR2 4353/4885S1PR4 4525/4885S1PR3 4454/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | S1PR2 876/4885S1PR4 757/4885S1PR3 808/4885 |
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | GABRA2, GABRA3, GABRB2 | S1PR2 2640/4885S1PR4 3761/4885S1PR3 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.